

## Special Issue

# Key Processes in Health and Disease Regulated by the Hippo Pathway

### Message from the Guest Editor

The Hippo pathway is known to participate in the genetic program that dictates one pre-defined size of an adult organ, in the presence of the correct nutrient availability. Organ size relies on a delicate balance between cell proliferation, apoptosis, and cell self-renewal events, all features controlled by the Hippo pathway. If, on one hand, the Hippo cascade seems to participate in all stages of development from fetus to adult life in healthy individuals, at the same time and in the presence of either mutations or altered expression in genes, as an aberrant function of proteins of this signaling cascade, it may be associated to disorders concerning cancer, cardiovascular pathologies, and inherited familial diseases.

In this Research Topic, we call for articles and reviews that are able to summarize, in an original and innovative view, the latest findings and molecular insights on the involvement of proteins, interactors, and upstream regulators in health and disease.

### Guest Editor

Dr. Giampaolo Morciano

1. Translational Research Center (CRT), Maria Cecilia Hospital, GVM Care & Research, 48033 Cotignola (RA), Italy
2. Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy

### Deadline for manuscript submissions

closed (15 February 2022)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/66352](https://mdpi.com/si/66352)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).